Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial

Study limitation reported by the research below: “The trial was industry-sponsored (AbbVie); readers should weigh this when assessing potential for reporting bias.”